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SUMMARY 
Dissolution rate data obtained with sulfathiazoie-povidone(PVP) co-precipitates and 
hydrocortisone-povidone co-precipitates were compared to cellophane membrane dif- 
fusion data obtained with the co-precipitates. The hypothesis, that the rate-limiting drug 
phases in the co-precipitate dissolution experiments were high energy amorphous phases 
of the drug, was tested. In regions of the dissolution rate studies where the carrier effects 
due to the PVP-drug complexes were small, the dissolution rates for the two PVP-drug 
systems agreed well with the results of the membr~e diffusion experiments. The normal- 
ized fluxes were found to be about 3.5 for the high energy phase of sulfathiazole and 14- 
18 for that of hydrocortisone. 
Previous reports from this laboratory have shown that co-precipitation of drugs with 
povidone (PVP) can significantly increase drug dissolution (Simonelli et al., 1969a and 
1969b). In addition, extensive solubility studies using the PVP-sulfathiazole system 
provided strong evidence to support the original postulate; that an amorphous form of 
drug is the controlling sulfa~i~ole phase promot~g the enhanced dissolution observed 
in these systems (Simonelii et al., 1976). The latter study also indicated that the co-pre- 
cipitation technique, in addition to enhancing dissolution may also permit the formulator 
to increase the apparent solubility of a given drug. If the increased solubility of a drug 
achieved on co-precipitation is due to the formation of a high energy amorphous phase 
rather than LO complex formation, then the e~~cement should be reflected in an 
increased membrane transport of the drug above unit activity. The potential to improve 
biological drug activity through enhanced membrane transport achieved by utilizing high 
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energy drug phases could be considerable, particularly in the case of topically administered 
drugs. The purpose of this report therefore was to explore the potential of the co-precipi- 
tation technique to enhance the membrane transport of sulfathiazole and hydrocortisone. 
In order to quantitatively study drug membrane transport, a cell utilizing a synthetic 
model membrane was developed, which allowed the mechanism of drug membrane trans- 
port from solutions of co-precipitates to be studied under well defined conditions. 
THEORETICAL 
When two well stirred primarily aqueous compartments are separated by a semiper- 
meable membrane (Fig. 1) the rate of transport (G), assuming drug binding is negligible, 
in the steady-state will be given by 
G = AP,(CD - C,) (1) 
where A is the surface area of the membrane, P, is the effective permeability coefficient 
and CD and CR are the drug concentrations in the donor and receptor compartments, 
respectively. In the case of transport across a porous membrane (Ho et al., 1980) P, is 
given by Eqn. 2: 
(2) 
where Pag and P,,, are the permeability coefficients due to the aqueous diffusion layer and 
the membrane respectively. 
When drug is present in bound and unbound form then Eqn. 1 may be written as 
G= I+"ic (CTD-CTR) (3) 
P 
Stirring bars 
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b 
F:g. 1. Schematic diagram of the Lucite diffusion cell. 
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where C, is the polymer concentration and C TD and CTR are the total bulk drug (free and 
bound) concentrations in the donor and receptor compartments, respectively; and K is 
the equ~b~um ~st~bution ~~~~t of drug to polymer. The mount of drug (w) in the 
cdl at any time is given by 
where V, and VR are the volumes of the donor and receptor corn~~~nts, re~~vely 
and C$, is the concentration at time t = 0 in the donor compartment. Combination of 
Eqn. 3 and 4, remarrangement and integration between the limits of t from 0 to t and C, 
from C$, to CTD when VD = VR = V gives 
log(~ - I) = *.30;:e:Cp) 
or in terms of CR 
A plot of the left-hand side of either Eqns. 6 or 7 vs time, t, should be linear with a slope 
of 2AP’/2.303V where P* = P&l + KC,). In addition, if C, is kept constant this slope 
should be inde~ndent of CTD. 
At early sampling times (i.e. when CR * 0) the initial transport rate Gi will be given 
according to Eqns. 1 and 3, by 
Gp Ap, 
1 + KC, CTD 
Therefore a plot of G/A vs CTD should have a slope of P&l + KC,). 
Reparation of co-precipitates 
a. Sulfathirlzoltt-PVP co-p?=ecipitates. Co-precipitates of sulfathiazole with PVP 10,000 
were prepared by the alcohol evaporation rne~~ des~~bed pre~ou~y (S~one~i et al., 
1969). 
b. Hydrocortisone-PVP coprecipitate. A weighed quantity of hydrocortisone I, was 
dissolved in a minimum volume of glass distilled absolute ethanol, in a round-bottom 
flask. The hydrocortlsone had been recrystallized from ethanol prior to use. A measured 
’ The Upjohn Company, Kalamazoo, Mich. 
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activity of tritium-labeled hydro~ortisone 2 was added to this solution. A sufficient 
quantity of PVP 3 with 10,000 molecular weight, to obtain a l-to-10 drug-PVP ratio, 
was further added and dissolved in this solution. The solvent was then flash evaporated 
in a rotary evaporator. To accelerate the evaporation process, the flask was placed in a 
50°C water bath. When the co-precipitate was formed, the flask was then Gonnected to a 
Cenco vacuum pump 4. A cold solvent trap was placed between the flask and the vacuum 
pump, The system was evacuated for about 1 h until a constant weight was reached. 
Fur~ermore, this assured removal of residual solvent from the co-precipitate. The flask 
containiig the co-precipitate was placed in a vacuum desiccator for a period of at least 
24 h. Then the ~-precipitate was scraped off the flask and converted to a fme powder 
with use of a mortar and pestle. The powder was stored in a vacuum desiccator in a 
light-free environment for future use. 
Mmbrune transport studies 
a. ~ep~a~~~~ of membranes. The membranes employed in our experiments were 
prepared from regenerated cellulase diaIysis tubing (Visking membrane) ’ having a flat 
width of 42 mm, a dry thickness of 21.8 pm and an average pore size of 2.4 nm. The 
membrane was cut into circles with a diameter of 38 mm, and washed with distilled water 
to remove the additives, such as glycerol and sulfur compounds, which were added for 
~ften~g and pre~~ation of the membr~e, respectively. Before use, the membr~e was 
soaked in distilled water to allow it to swell. 
Each cell consisted of two transparent cylindrical Lucite compartments of depth 5.2 
cm and with an opening 3.2 cm di~eter. The volume of each compa~ment was 40 ml. 
Two side tubes of Lucite on each compartment of the cell were provided; one for inser- 
tion of a propeller, which was used (SO rpm) with a Hurst model CA synchronous motor, 
and the other for samp~ng (schematic diagr~ of the diffusion cell is i~ustrated in Fig. 
1). The cellulose membrane was placed between the two compartments and a Teflon 
gasket ring with 3.2 cm i.d. and 0.5 mm thick was placed over the membr~e to ensure 
sealing of the sides of the two compartments when they were screw sd together. A Teflon 
tape was wrapped around the joint on the cell to prevent water penetration from the con- 
stant temperature bath. A brass tube was provided to hold the cell and suspend it in a 
desired position in the constant temperature bath. The donor and receptor compartments 
were then fdled ~u~t~eou~y with the media prepared for tr~sport experiments. 
S~fat~ole was assayed s~~trophotometric~y 6 as previou~y desc~bed. Hydra- 
cortisone in PVP solutions was assayed radiometrically 7 and also spec~ophotometric~y 
2 New England Nuclwr, Boston, Mass. 
’ GAF Corp., New York, N.Y. 
4 Central Scientific, Chicago, Ill. 
s Union Carbide. 
6 Beckman DB, Beckman h&mments, Irvine, CaIif, 
’ Beckman Liqtiid S~~t~ation mounter, Model LS200, Beckman Instruments, Irvine, Calif. 
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at 247 nm. Saturated solutions in redistilled water and in PVP solutions were prepared as 
described by Kabasakalian et al. (1966) and hydrocortisone oxidation was minimized by 
adopting the procedures outlined by Monder (1968). The experimental temperature was 
25Oc. 
Dissolution procedure 
The apparatus used for dissolution rate determinations was similar in design to that 
previously described by Kwan et al. (1977) and employed a water-jacketed cylinder of 
internal diameter 3.8 cm. The aqueous dissolution medium volume used was 40 ml and 
the experimental temperature 25°C. The drug pellet surface area available for dissolution 
was 1.266 cm2. 
RESULTS AND DISCUSSION 
The results of preliminary exploratory studies of the transport of sulfathiazole through 
a cellophane membrane from a sulfathiazole-PVP (1 : 3) coprecipitate are illustrated in 
Fig. 2. Previous investigations have established the presence of a stabilized high energy 
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Fig. 2. Fluxes of sulfathiazole obtained in a diffusion cell with a cellophane membrane barrier. 
Volumes of donor and receptor chambers were 40 ml. Experimental temperature 25°C. Key: 0, 
saturated solution of 1 : 3 drug-PVP in 5% PVP solution; l , saturated solution of crystalline drug; A, 
saturated solution of crystalline drug in 5% PVP. 
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form of sulfathiazole at this weight fraction (Simonelli et al., 1969a). The flux obtained 
from a 5% PVP aqueous solution saturated with the sulfathiazole-PVP co-precipitate was 
significantly greater than that obtained from solutions saturated with crystalline drug. 
The ratio of the slopes was 3.5 : 1, which is comparable with the 3.8-fold thermodynamic 
fugacity (or activity) difference between crystalline sulfathiazole and the high energy 
amorphous phase estimated previously from dissolution (Simonelli et al., 1969a) and 
solubility experiments (Simonelli et al., 1976). Transport data obtained using solutions 
saturated with crystalline drug and containing 5% PVP gave fluxes slightly higher 
(-IO-15%) than those obtained in the absence of PVP. Some increase in flux was 
expected since transport measurements with pure PVP revealed measurable transfer of 
polymer giving permeability coefficients 0.1-0.05 of those for the drug. In addition, 
under the experimental conditions employed, the aqueous diffusion layers will contribute 
to the estimated permeability coefficient and thus the overall effective resistance could be 
reduced, as predicted by Amidon et al. (1979), in saturated media containing polymer- 
bound drug. However, as the data show, these effects do not contribute sizeably to the 
flux data obtained. The sulfathiazole results therefore support the contention that the 
high energy phase concept is valid and the “carrier’* effect of the drug PVP complex in 
solution is at most an order of magnitude smaller than the thermodynamic effect. 
Hydrocortisone-PVP Co-pre@itate dissolution 
Since previous studies have established that co-precipitation of certain steroids (includ- 
ing hydrocortisone and methylprednisolone) with PVP can increase the relative drug dis- 
solution rate orders of magnitude higher than that observed with sulfathiazole (Mehta et 
al., 1971), a more detailed investigation of the dissolution and membrane transport 
properties of hydrocortisone was undertaken to more firmly establish the high energy co- 
precipitate phase concept, 
TABLE 1 
EXPERIMENTAL RELEASE RATES OF HYDROCORTISONE AS A FUNCTION OF PVP WEIGHT 
FRACTION IN COPRECIPITATE 
PVP weight fraction Absolute rates 
(G - ml-’ -mid’ X IO’) 
Relative a rates 
Initial Limiting Initial Limiting 
0.4 (I : 1.5) 0.68 0.14 
0.5 (I : I) 1.33 0.22 
0.6 (1.5 : I) 1.32 0.60 
0.7 12.3 : I) 6.36 
0.8 (4 : I.) 5.28 - 
0.9 (9 : I) 2.96 
0.95 (19 : I) 2.12 
-- 












B it u 
,*1-*.1**.fl**.‘** 
320 24O 16' 60 32O 24O 16" 8' 
20 20 
Fig. 3. a: comparison of X-ray diffraction spectra of 1 : 10 hydrocortisone to PVP co-precipitate and 
PVP (mol. wt. 10,000). Key: A, co-precipitated powder; B, PVP powder. b: comparison of X-ray dif- 
fraction spectra of mechanical mixture of 1 : 10 hydrocortisone to PVP powder and crystalline hydro- 
cortisone. Key: A, mechanical mixture; B, crystal powder. 
Hydrocortisone dissolution rates obtained, as a function of PVP weight fraction in co- 
precipitate are summarized in Table 1. The maximum relative enhancement in dissolution 
rate was of the order of 70-fold. Dissolution profiles at lower PVP weight fractions were 
non-linear. The initial rates for the 0.5 and 0.6 weight fraction systems are at a plateau 
corresponding to a rate of 14-15 times that of the pure drug. Dissolution data for the 
0.4, 0.5 and 0.6 PVP weight fraction systems were also obtained in media containing 5% 
and 10% PVP in an attempt to inhabit nucleation and/or crystal growth which can occur 
during co-precipitate dissolution (Simonelli et al., 1969a; Mehta et al., 1971). The initial 
dissolution rates increased in the PVP-containing media for all 3 co-precipitates, the rate 
for the 0.4 PVP weight fraction system becoming equal to that of the 0.5 and 0.6 weight 
fraction system. However, the dissolution profiles remained curved. These results suggest 
that a high energy form of hydrocortisone, with an activity of 14-15 times that of the 
pure drug is present in PVP co-precipitates and at the lower PVP weight fractions, even in 
the presence of up to 10% PVP, reconversion to the more stable form occurs during dis- 
solution. In order therefore to minimize this potential for nucleation and crystal growth 
during membrane transport experiments the 10 : 1 (PVPdrug) co-precipitate system was 
used. X-ray diffraction data showing the essentially amorphous state of hydrocortisone in 
this system are shown in Fig. 3. 
Hydrocortisune membrane transport 
Cellulose membrane transport data for saturated hydrocortisone solutions as well as 
co-precipitate-containing systems are summarized in Fig. 4. In co-precipitate-containing 
systems the concentration of PVP was adjusted to 9.5%. The flux from the PVP-contain- 
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Fig. 4. Fhtxes of radioactive labeled hy~ocortisone at 25°C obtained experimentally in a diffusion 
cell with a cellulose membmne barrier. All ~per~turated soh&ons were prepared by dissolving pre- 
determined amounts of a 1 : 10 hydrocortisone-PVP co-precipitate into water and adjusted PVP con- 
centration to 9.5%. Volumes of donor and receptor chambers were 40 ml. Key: A, supersaturated drug 
solution containing 4.54 mg/ml hydrocortisone and 9.5% PVP; o, supersaturated drug solution con- 
taining 3.41 mg/ml hydrocortisone and 9.5% PVP; l , supersaturated drug solution containing 2.27 
rn~rn1 hydrocortisone and 0.5% PW, 4, saturated solution of hydr~ortisone in 9.5% PVP (0.65 
mg~rnl)~ a, saturated solution of hydrocortisone in water (0.38 gm~ml). 
ing s&tion, saturated with crystalline hydro~ortisone, is about 15% higher than from the 
aqueous solution, an effect similar to that observed with sulfathiazole. Fluxes obtained 
from co-precipitate-containing systems were, however, conside,.ably higher, the flux 
increasing with increasing hydrocortisone content. A comparison of the initial slopes indi- 
cates that the highest flux is about 10 times that of unit activity. The data in Fig. 4 are 
plotted according to Eqn. 6 in Fig. 5. All the data points from Pi-cont~~g systems 
lie on the same line, basting good agreement of the data with the proposed model. The 
greater slope for the hydrocortisone-water system reflects the relationship between P* 
and Pm. When the concentration of hydrocortisone was increased above 4.6 mg/ml 
nucleation was observed in the donor solution and data deviated from the model. 
Since attainment of higher transport rates seemed to be limited by recrystallization, a 
number of nucleation and crystal growth inhibitors were screened for hydrocortisone 
crystal growth inhibition. As a result, Clayton yellow and dodecylamine hydrochloride 
were selected for use in membrane flux exper~ents. 
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In the presence of 0.05% Clayton yelfow, co-precipitate sohrtions, cont~g up to 
6.5 mg ml-’ of hydracortisone, could be prepared in aqueous solution of 9.5% PVP with- 
out visible cloudiness developing during the membrane transport studies. Data from these 
experiments are also included in Fig. 5 and are co-incidental with data obtained at lower 
drug concentrations in the absence of inhibitor. These results suggest that Clayton yellow 
does not inrkrencc the membr~e ~rmeab~~ but enhances hydr~o~i~ne transport by 
preventing crystallization in the donor compartment. At higher hydrocortisone concen- 
trations visible nucleation did occur and the trusty rate declined rapidly with time. 
Estimates were made of the hydrocortisone initial transport rates. The actual and nor- 
m~zed vahtes obt~ed are plotted, together with those estimated in the absence of 
Clayton yellow, vs hydroco~isone total con~ntration in Fig. 6. The good linear refation- 
ship which includes the data from solutions which became cloudy is evident thus support- 
ing the presence of a h&h energy phase in co-precipitate systems. The relative m~mum 
enhancement in membrane transport brought about by comprecipitate was 18-19”fold 
and in systems in which no nucleation was observed, 14-l S-fold. These values are similar 
Time (hours) 
Fig. 5. Semi-log plot of (CO - ZCp}/Co vs time for transport of hydrocortisone across dialysis mem- 
brane. Key: A - P, saturated solution of crystalline h~~ocortisone in water; and 0, saturated solution 
of crystalline hydro~rti~na in 0.05% Clayton yellow. B - or ~precipi~te of hydr~ortisone dis- 
solved in water; and I, in 0.05% Clayton yellow. 
Fig. 6. Initial hydro~ortisone tr~sport rate vs hydrocortisone conc~n~ation in 9.5% PVP prepared 
from 10 : I (PVP-drug) coprecipitate. Also included is the normaliied ffux which is defined: (flux 
with ~opre~ipitate)~(ffux with saturated solution of crystalline drug in 9.5% PVP). Key: @, PVP 9.5%; 
a, PVP 9.5% plus Clayton yellow, 0.05%; A, PVP 9.5% plus dodecy~m~e HCI 1%; a, systems in which 
visible nucleation occurred during the experiment; - - - - - -, includes contribution fxom aqueous diffu- 
sion layers; -, assumes only membrane control. 
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in ma~itude to the relative e~an~ments observed in the dissolution rate experiments. 
Also included in Fig. 6 are data obtained using dodecylamine HCl (1%) as nucleation 
inhibitor. In the presence of dodecylamine a much lower effective permeability coeffi= 
cient (P,J was obtained, indicating posOible solubilization of the drug by dodecylamine 
HCl. As a result, for a given hydrocortisone concentration a much lower membr~e flux 
was observed (Fig. 6). With this agent solutions containing as high as 18 mg/ml of hydro- 
cortisone were required before visible nucleation occurred in the donor chamber. How- 
ever, in these systems the limiting kydrocortisone transport rates were still only 15-16 
times unit activity. 
In Fig. 6 the expected relation~ip (Eqn. 7) between GifA and CTD using Pe calculated 
from Fig. 5 is included (dotted line), K being estimated from the solubility data. In addi- 
tion the relationship expected if P, = Pm is also shown (upper line). Pm was estimated 
from Eqn. 2 using Pas determined from previous base line studies of the limiting stirring 
rate-dependent transport of benzoic acid in the same cell. The de.ta in Fig. 6 lie closer to 
the “P,” line, su~est~g, as predicted by Amidon (1979), that the presence of bound 
drug in the system can eliminate the effect of the aqueous diffusion layer, and this also 
contributes to the enhanced membrane transport. 
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